Giuliani Nicola, Rizzoli Vittorio, Roodman G David
Cattedra e Unità Operativa (UO) di Ematologia-Centro Trapianti Midollo Osseo (CTMO), Università Degli Studi di Parma, Italy.
Blood. 2006 Dec 15;108(13):3992-6. doi: 10.1182/blood-2006-05-026112. Epub 2006 Aug 17.
Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.
多发性骨髓瘤(MM)是一种浆细胞恶性肿瘤,其特征在于具有高诱导溶骨性骨病变的能力。MM中的骨破坏是由于骨髓瘤细胞附近破骨细胞形成增加和活性增强所致。然而,组织形态计量学研究表明,患有溶骨性骨病变的MM患者成骨细胞数量较少且骨形成减少。这种受损的骨形成在骨破坏过程中起关键作用。最近,MM细胞诱导成骨细胞抑制所涉及的生物学机制已开始得到阐明。在本文中,对MM中成骨细胞抑制的病理生理学进行了综述。